5EDP
EGFR kinase (T790M/L858R) apo
Summary for 5EDP
Entry DOI | 10.2210/pdb5edp/pdb |
Related | 5EDQ 5EDR |
Descriptor | Epidermal growth factor receptor (1 entity in total) |
Functional Keywords | protein kinase, transferase-transferase inhibitor complex, transferase/transferase inhibitor |
Biological source | Homo sapiens (Human) |
Cellular location | Cell membrane; Single-pass type I membrane protein. Isoform 2: Secreted: P00533 |
Total number of polymer chains | 1 |
Total formula weight | 37549.40 |
Authors | Eigenbrot, C.,Yu, C. (deposition date: 2015-10-21, release date: 2015-12-02, Last modification date: 2024-03-06) |
Primary citation | Hanan, E.J.,Baumgardner, M.,Bryan, M.C.,Chen, Y.,Eigenbrot, C.,Fan, P.,Gu, X.H.,La, H.,Malek, S.,Purkey, H.E.,Schaefer, G.,Schmidt, S.,Sideris, S.,Yen, I.,Yu, C.,Heffron, T.P. 4-Aminoindazolyl-dihydrofuro[3,4-d]pyrimidines as non-covalent inhibitors of mutant epidermal growth factor receptor tyrosine kinase. Bioorg.Med.Chem.Lett., 26:534-539, 2016 Cited by PubMed Abstract: The treatment of epidermal growth factor receptor (EGFR)-driven non-small cell lung cancers with the T790M resistance mutation remains a significant unmet medical need. We report the identification of 4-aminoindazolyl-dihydrofuro[3,4-d]pyrimidines as non-covalent inhibitors of EGFR, with excellent activity against the T790M resistance double mutants and initial single activating mutants. Using an optimization strategy focused on structure-based design and improving PK properties through metabolite identification, we obtained advanced leads with high oral exposure. PubMed: 26639762DOI: 10.1016/j.bmcl.2015.11.078 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (2.9 Å) |
Structure validation
Download full validation report